Low-dose Procainamide: Low Risk of Complications with Long-term Use

Overview

Journal J Natl Med Assoc

Publisher Elsevier

Specialty General Medicine

Date 1983 Jul 1

PMID 6887275

Authors

C van Pham

J Noguchi

F P Quismorio Jr

L J Haywood

Affiliations

Soon will be listed here.

Abstract

The incidence of procainamide-induced drug reactions was studied prospectively in 55 patients receiving long-term therapy with a mean duration of 23 months. New symptoms that occurred in 13 patients after the drug was started were similar to complaints presented by 25 patients before the medication was started. Duration of therapy was positively correlated with new symptom occurrence (P < .05) but not with age, sex, dose, or dose interval. Other concomitant drugs did not influence the results. Antideoxyribonucleoprotein antibodies were positive in 27 patients (55 percent) and in seven of 13 with new symptoms; female sex (P < .05) and increasing age (P < .05) favored a positive test. Anti-DNA antibodies were not found in any patients. Procainamide, at a mean dose of 1.5 g/day, was judged to be therapeutically effective by the clinic staff independent of this study; the drug was not discontinued in any patient because of the severity of symptoms.

References

Fakhro A, Ritchie R, LOWN B . Lupus-like syndrome induced by procainamide. Am J Cardiol. 1967; 20(3):367-73. DOI: 10.1016/0002-9149(67)90060-4. View

Siegel M, Lee S, Peress N . The epidemiology of drug-induced systemic lupus erythematosus. Arthritis Rheum. 1967; 10(5):407-15. DOI: 10.1002/art.1780100502. View

SVEC K, Veit B . Age-related antinuclear factors: immunologic characteristics and associated clinical aspects. Arthritis Rheum. 1967; 10(6):509-16. DOI: 10.1002/art.1780100604. View

DUBOIS E . Procainamide induction of a systemic lupus erythematosus-like syndrome. Presentation of six cases, review of the literature, and analysis and followup of reported cases. Medicine (Baltimore). 1969; 48(3):217-28. View

Alarcon-Segovia D . Drug-induced lupus syndromes. Mayo Clin Proc. 1969; 44(9):664-81. View

Molina J, DUBOIS E, Bilitch M, Bland S, Friou G . Procainamide-induced serologic changes in asymptomatic patients. Arthritis Rheum. 1969; 12(6):608-14. DOI: 10.1002/art.1780120608. View

KOSOWSKY B, Taylor J, LOWN B, Ritchie R . Long-term use of procaine amide following acute myocardial infarction. Circulation. 1973; 47(6):1204-10. DOI: 10.1161/01.cir.47.6.1204. View

Woosley R, Drayer D, Reidenberg M, Nies A, Carr K, OATES J . Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med. 1978; 298(21):1157-9. DOI: 10.1056/NEJM197805252982101. View

Jones G, George T, Bradley R . Procainamide-induced hemolytic anemia. Transfusion. 1978; 18(2):224-7. DOI: 10.1046/j.1537-2995.1978.18278160589.x. View

10.

Bell W, Boss G, Wolfson J . Circulating anticoagulant in the procainamide-induced lupus syndrome. Arch Intern Med. 1977; 137(10):1471-3. View

11.

Whittle Jr T, Ainsworth S . Procainamide-induced systemic lupus erythematosus. Renal involvement with deposition of immune complexes. Arch Pathol Lab Med. 1976; 100(9):469-74. View

12.

Lundberg W, Farber L, Cadman E, Skeel R . Spontaneous acute leukemia in polycythemia vera. Ann Intern Med. 1976; 84(3):294-5. DOI: 10.7326/0003-4819-84-3-294. View

13.

Henningsen N, Cederberg A, Hanson A, Johansson B . Effects of long-term treatment with procaine amide. A prospective study with special regard to ANF and SLE in fast and slow acetylators. Acta Med Scand. 1975; 198(6):475-82. View

14.

Winfield J, Davis 4th J . Anti-DNA antibody in procainamide-induced lupus erythematosus. Determinations using DNA fractionated by methylated albumin-Kieselguhr chromatography. Arthritis Rheum. 1974; 17(2):97-110. DOI: 10.1002/art.1780170202. View

15.

KAPLAN A, Zakher F, Sabin S . Drug-induced lupus erythematosus with in vivo lupus erythematosus cells in pleural fluid. Chest. 1978; 73(6):875-6. DOI: 10.1378/chest.73.6.875. View

16.

McCrum I, Guidry J . Procainamide-induced psychosis. JAMA. 1978; 240(12):1265-6. DOI: 10.1001/jama.240.12.1265. View

17.

Rotmensch H, Yust I, Siegman-Igra Y, Liron M, ILIE B, VARDINON N . Granulomatous hepatitis: a hypersensitivity response to procainamide. Ann Intern Med. 1978; 89(5 Pt 1):646-7. DOI: 10.7326/0003-4819-89-5-646. View

18.

Sahenk Z, Mendell J, Rossio J, Hurtubise P . Polyradiculoneuropathy accompanying procainamide-induced lupus erythematosus: evidence for drug-induced enhanced sensitization to peripheral nerve myelin. Ann Neurol. 1977; 1(4):378-84. DOI: 10.1002/ana.410010409. View

19.

LADD A . Procainamide-induced lupus erythematosus. N Engl J Med. 1962; 267:1357-8. DOI: 10.1056/NEJM196212272672608. View

20.

Beaulieu A, Quismorio Jr F, Kitridou R, Friou G . Complement fixing antibodies to DS-DNA in systemic lupus erythematosus: a study using the immunofluorescent Crithidia luciliae method. J Rheumatol. 1979; 6(4):389-96. View